95results about How to "Reduce clinical dosage" patented technology

A Chinese medicine in the form of tablet, capsule, particle, or oral liquid for treating cardiovascular and cerebrovascular diseases is prepared from 16 Chinese-medicinal materials including Chuan-xiong rhizome, Chinese angelica root, red peony root, astragalus root, etc. Its preparing process is also disclosed.

The invention relates to preparation and application of a novel targeting peptide for specifically inhibiting tumor cell metastasis. The preparation method disclosed by the invention is technically characterized in that a polypeptide TMTP1-GG-D(KLAKLAK)2 which can simultaneously identify high metastasis potential tumor cells and inhibit tumor cell growth and metastasis is prepared, and antimicrobial peptides can be specifically transported into malignant tumor tissues and local metastasis through the polypeptide, so that the high metastasis potential tumor cells can be selectively killed, an obvious toxic or side effect is avoided, the tumor growth and metastasis are effectively inhibited, the polypeptide is expected to become a novel antitumor medicine, and the key defects in the conventional tumor molecule targeted therapy technology and practice can be overcome. The invention aims to provide the polypeptide which can simultaneously and specifically identify and restrict tumor cells with high metastasis potential tendency, so that the problems of large side effects, low specificity and the like existing in existing targeting medicines are solved, highly-efficient and specific tumor inhibiting and killing effects are expected to be achieved in clinical treatment, and the treatment aim of greatly killing the tumor cells in a targeted mode can be furthest achieved due to the novel polypeptide. In addition, the invention also can provide a novel design mode for subsequent other molecular therapy.

The invention discloses tetanus toxin T cell epi position peptide and human B lymphocyte activate and gene interfusing albumen. It could activate CD4+T cell to take cell action, promote body liquid immunity level. It adopts step clone to construct TT and BLyS interfusing gene and gain high efficiency expression in coliform bacteria. It conquers the immunity tolerate of the body.

The present invention provides a combined pharmaceutical composition of paclitaxel and CDKS kinase inhibitors, comprising active ingredients and pharmaceutically acceptable excipients, characterized in that: the active ingredients are composed of paclitaxel and CDK4 / 6 kinase represented by formula I Inhibitors or pharmaceutically acceptable salts thereof, the mass ratio of paclitaxel and CDK4 / 6 kinase inhibitors or pharmaceutically acceptable salts thereof in the active ingredient is (2‑8):1. The pharmaceutical composition has good anticancer curative effect and low toxic and side effects; due to the sensitivity of CDK4 / 6 kinase inhibitors to paclitaxel, the combination of the two produces a synergistic effect, thereby reducing the clinical dosage of capecitabine and reducing the large dosage Toxic and side effects produced by using capecitabine can improve the safety index of clinical treatment and have good clinical application prospects.

The invention discloses a drug composition for treating neurasthenia and preventing senile dementia. The drug composition comprises the following raw materials in percentage by mass: 1%-10% of malania oleifera nervonic acid, 1%-10% of helicid, 1%-10% of semen coicis lactone and the balance of auxiliary materials. The drug provided by the invention is helpful for prolonging the sleeping time of old people; the semen coicis lactone is capable of preventing cancers and inhibiting proliferation of various cancer cells; malania oleifera nervonic acid, helicid and semen coicis lactone are combined for effectively preventing and controlling the occurrence of the senile dementia and healing the senile dementia; a safe and effective plant composition extracted from pure plants is provided for the whole world with increasingly severe aging problems. According to the drug composition, the raw materials are reasonable in medicine compatibility and are all from natural plants; meanwhile, a preparation method of the drug composition provided by the invention is strong in operability; especially, an extraction process is involved according to the chemical properties of the effective ingredients of various Chinese herbal medicines, and the effective ingredient content of obtained extract is high; the drug composition has the advantages of high drug effect, low clinical dosage and the like, and the process is stable and suitable for industrial mass production.

A kind of amalgamation albumen combined peptide and hrn TNF specificity of the knub neconatal vein and its preparation method is disclosed in the invention. The knub necro-gene is a kind of multi-functional cell gene, which participates in immunity metabolizating modulation of the economy, has restriant and cell poison action to growth of some cancer cells. The invention wipes off 1-7 bit amino acid of the amido end of the knub necro-gene, changes 8-10 bit amino acid into Arg-Lys-Arg and 157 bit amino acid of carboxyl end into Phe, and composes new type high effect and low poison knub necro-gene nrhTNF. On the basis, prepared amalgamation albumen combined peptide and nrhTNF specificity ofthe knub neonatal vein can enrich at the place of knub neonated vein by use of the cyclopeptide CRGDC containing five amino acids elected from phage revelation library.

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

This invention supplies a drug composition used to cure asthma, bronchitis, chronic obstructive pulmonary disease, and other respiratory diseases. The drug contains two active constituents: gingko-leaf extract and epinephrine receptor stimulator. In experiment we get a unexpected effect: the gingko-leaf extract engenders notable synergism effect withª‰-epinephrine receptor stimulator, and this has crucial meaning to clinical therapy of asthma, bronchitis, chronic obstructive pulmonary disease. Compound preparation types of aerosol, spray, powder aerosol, capsule, slow release capsule, soft capsule, common tablet, slow release tablet, disperse tablet, buccal tablet, droplet, and so on are not only propitious to quickly exert drug curative effect, but also are convenient to take.

The invention provides a medicament for preventing and treating neurologic damage and related diseases thereof, and in particular relates to the application of a neurotrophic factor mixture secreted by adult stem cells from fat or an adult stem cell in vitro culture from the fat in preventing and / or treating the neurologic damage and the related diseases thereof. The neurotrophic factor mixture exists in the cell in vitro culture; the neurotrophic factor mixture and the cell in vitro culture can generate a synergistic effect, which reinforces activity greatly, reduces clinical dose obviously, reduces treating cost and reduces side effects; and the medicament can be effectively used for the neurologic damage and the related diseases thereof, such as preventing and / or treating the anoxic ischemic encephalopathy without processing steps such as further extracting, purifying and the like or adding a carrier, which fills the gap of the deficiency of conventional preventing and treating means for the neurologic damage and the related diseases thereof, simultaneously reduces the side effects and untoward effects, and further contributes to the reduction of the production cost of the medicament and popularization and application.

A Chinese medicine for treating cardiovascular and cerebrovascular diseases and ischemic apoplex is prepared from red peony root, capejasmine fruit and astragalus root. The prescription and preparing process of its injection and its other clinical forms are also disclosed.

The invention relates to a novel medicine composition capable of synergistically enhancing the capacity of restraining tumor growth. The composition contains tetrandrine and chloroquine. Researches prove that the combined medication of the tetrandrine and the chloroquine with a certain concentration can effectively induce the death of tumor cells; a BALB / c nude mouse is vaccinated with a tumor cell of a person, a tumor is formed, a nude mouse heterograft model is established, and the monitoring on the growth curve of the tumor and the weight of the tumor indicates that the combined medication has the obvious effect of restraining the tumor growth. The invention confirms that the antitumor effect of the medicine combination containing the tetrandrine and the chloroquine is much better than that of the single tetrandrine or the single chloroquine, the medicine combination has an obvious synergistic effect, the basis of clinical combined application of the tetrandrine and the chloroquine for resisting the tumor is provided, and the medicine combination is a potential tumor medicine with high efficiency and low toxicity.

A Chinese medicine for treating cardiovascular and cerebrovascular diseases is prepared from red peony root and capejasmine fruit. The prescription and preparing process of its injection and its other clinical forms are also disclosed.

The invention provides a eucalyptus oil doxycycline hydrochloride self-microemulsion g for livestock and a preparation method and application of the eucalyptus oil doxycycline hydrochloride self-microemulsifon. The self-microemulsion comprises the following components in proportion of 50-250 g / L of doxycycline hydrochloride raw drugs, 1-50 g / L of a solvent, 0.1-2 g / L of an antioxidant, 80-300 g / La surfactant, 60-300 g / L an assistance surfactant, and 100-450 g / L of an oil phase. The self-microemulsion is good in stability, uniform in particle size distribution, and good in dispersibility. Eucalyptus oil is used as the oil phase of a phase converting method, and the problem of dissolving of folium eucalypti essential oil is solved. Besides, the eucalyptus oil has mild stimulation effects onrespiratory tract nasal cavity and endotracheal mucosa, can promote mucus secretion and can dredge logged nasal cavity and logged bronchus. In addition, the self-microemulsion is simple in preparation method, mild in condition, and low in production cost, can be used for preparing medicines or feed additives for livestock, and has high economic value and biology promotion value.

The invention provides a preparation method of an anti-neweastle disease virus specific transfer factor. The method comprises the following steps: selecting a healthy chicken as an experiment chicken to carry out supplementary immunization of a newcastle disease inactivated vaccine; monitoring the level of an immune antibody of the newcastle disease vaccine inside the experiment chicken body; taking splenic organs of the experiment chicken in a sterile condition when the level of the antibody achieves 28-29; and processing the splenic organs of the chicken, so as to obtain the anti-neweastle disease virus specific transfer factor. By adopting the anti-neweastle disease virus specific transfer factor disclosed by the invention, the specific immune effect of the chicken body on a neweastle disease virus antigen can be improved; normal cells of the body can be prevented from being infected by the virus. Thus, the transfer factor disclosed by the invention can play the roles in preventing the neweastle disease virus infection and protecting normal cells of the body from being damaged by the neweastle disease virus, so as to reduce the morbidity; meanwhile, the chicken infected by the neweastle disease virus can be treated by using the transfer factor. Therefore, the clinical symptoms can be effectively improved; the recovery rate is increased; the mortality is reduced.

The invention discloses an organic acid lithium amino acid salt. An organic acid lithium is one or more of lithium isobutyrate, lithium n-butyrate, lithium lactate, lithium citrate or lithium cholesterol; an amino acid is one of L-proline, valine, lysine or artificially synthesized amino acid; and the organic acid lithium amino acid salt is a salt formed by the organic acid lithium and the amino acid. The invention also discloses a crystal form, a preparation method and application of the salt. The organic acid lithium amino acid salt has a positive curative effect and a prevention effect on repeated attack of mania and depression in bipolar affective disorders, can delay degenerative diseases of a central nervous system to achieve better distribution of the central nervous system, and reduces the clinical dosage of the lithium salt while enhancing the curative effect of the central nervous system diseases, so as to avoid the occurrence of peripheral adverse reaction.

The invention discloses a preparation method of stem cell factor liposome for repairing damaged tissues. The preparation method comprises the following steps: step 1, separating and culturing canine adipose-derived mesenchymal stem cells; 2, digesting the cultured canine adipose tissue-derived stromal cells, crushing, centrifuging, filtering and carrying out ultrafiltration to obtain a stem cell extracting solution; step 3, mixing the lipidosome prepared in advance with the stem cell extracting solution; carrying out ultrasonic treatment to obtain a stem cell factor liposome suspension, addingsodium propionate, uniformly mixing, and filtering to obtain stem cell factor liposome solution. The method has the advantages that the absorption rate of the stem cell factors can be increased, theactivity of the stem cell factors can be protected, the loss of effective components can be reduced, and the utilization rate of the effective components can be effectively increased. Meanwhile, the invention also discloses the stem cell factor liposome for repairing damaged tissues, which is prepared by the method, and stem cell factors in the preparation are pure natural components, so that thepreparation is safe to apply, free from toxic and side effects, free from drug residues, high in activity, small in clinical dosage and quick to take effect.

The invention provides a pharmaceutical composition containing sunitinib as well as a preparation and an application of the pharmaceutical composition. On the basis of the original sunitinib, at leastone tyrosine kinase receptor inhibitor, especially apatinib and / or axitinib, is further added to generate a very significant synergistic effect with the sunitinib, so that the proliferation of cancercells is obviously inhibited, and the sunitinib has very significant killing efficiency on the cancer cells. The pharmaceutical composition provided by the invention can obviously improve the problemof serious drug resistance caused by singly adopting sunitinib in the prior art and the problem of obviously reduced treatment effect when the conventional use amount of sunitinib is reduced; clinical treatment efficiency is greatly improved, treatment toxic and side effects of a patient are reduced, a new scheme is provided for clinical treatment, and the traditional Chinese medicine compositionhas very wide market prospects and extremely important social significance.

The invention provides composition for treating enterovirus infection and a drug combination method and particularly provides composition for inhibiting enteroviruses. The composition comprises a first active ingredient and a second active ingredient, wherein the first active ingredient is a 3D protein inhibitor of enterovirueses such as EV71, and the second active ingredient is a capsid protein inhibitor of enteroviruses such as EV71. Experimental results show that the pharmaceutical composition has a remarkable synergistic function, and cytotoxicity of the composition in detected combination concentration is not enhanced.

The invention provides antitumor pharmaceutic preparation composition which is prepared from IRF-beta and an IDO inhibitor or the IFN-beta and a AhR inhibitor. The antitumor pharmaceutic preparation composition can kill differential tumor cells and also can kill dormant tumor cells and has an effect of completely eliminating tumor cells.

The invention provides a compound shown as the formula (I), wherein R1 is substituted or unsubstituted aryl or cycloalkyl, the aryl or the cycloalkyl optionally contains heteroatom such as N, S, and O in the aromatic ring or cycloalkyl ring, and the substituent is alkyl, alkoxyl or halogen; and R is H or substituted or unsubstituted phenyl. The invention also discloses a preparation method of the compound shown as the formula (I) and the application in the preparation of antiviral drugs.

The invention provides an antitumor drug composition, which is prepared from an active ingredient and a pharmacologically acceptable ingredient. The antitumor drug composition is characterized in thatthe active ingredient is prepared from gemcitabine and a CDK4 / 6 kinase inhibitor as shown in a formula I or pharmacologically acceptable salt thereof; the mass ratio of the gemcitabine and the CDK4 / 6kinase inhibitor or the pharmacologically acceptable salt thereof is (2 to 8):1. The drug composition is good in anticancer effect and low in toxic and side effects; due to the sensitivity of the CDK4 / 6 kinase inhibitor on the gemcitabine, the CDK4 / 6 kinase inhibitor and the gemcitabine are combined to produce a synergistic effect, so that the clinic dosage of capecitabine is reduced, the toxic and side effects produced by using a great amount of capecitabine are reduced, a clinic treatment safety index is improved, and a better clinic application prospect is realized.

The invention provides a new application of dracorhodin A, including an application of dracorhodin A in preparation of hypoglycemic drugs, health-care products or functional foods, and further including an application of dracorhodin A in preparation of an alpha-glucosidase activity inhibitor. The application creatively finds that dracorhodin A can inhibit the activity of alpha-glucosidase, and theinhibitory activity of dracorhodin A is far higher than that of acarbose serving as a clinical drug. The invention also provides a hypoglycemic composition, which comprises dracorhodin A and pharmaceutic adjuvants or health-care product adjuvants, and is used as a pharmaceutical preparation or a health-care product preparation.

The invention provides a composition and application thereof, and particularly provides a composition for decreasing blood sugar. The composition contains a first active component with berberine being an effective component and a second active component with timosaponin being the effective component; moreover, the effective component ratio V1 (mg: mg) of the first active component to the second active component is (1.5-6): 1. The composition can fast and effectively decrease the blood sugar and the drug feeding dose of the composition can be remarkably lowered at the same time, and adverse reactions of drugs can be reduced and a safe window is expanded.

The present invention relates to a targeted ultrasound contrast agent for enhancing the ultrasound diagnosis of carotid atherosclerosis and a preparation method thereof. It is prepared from phospholipid and biological inert gas, which realizes the carotid arteriosclerosis targeting of ultrasound contrast agent at low cost and enhances the ultrasound imaging effect of carotid arteriosclerosis.

The present invention discloses synergistic effects and applications of a series of compositions comprising magnolol, honokiol and a nonsteroidal antiinflammatory drug, wherein the chemical formulas of magnolol and honokiol are represented by a formula (I), and the chemical formula of the nonsteroidal antiinflammatory drug is represented by a formula (II). The invention further relates to applications of the compositions in anti-inflammatory drugs, drugs for skin, cosmetic protection, and other fields. The formulas I and II are defined in the specification.

The invention relates to the technical field of medical biological detection, and provides an application of rattlerin in preparing an anti-fungal drug sensitizer, an anti-fungal drug sensitizer taking rattlerin as an active ingredient and an anti-fungal combination preparation. According to experimental measurement, when fluconazole and rattlerin are combined, FICI of all experimental strains isless than or equal to 0.50, so that a strong synergistic effect is shown, meanwhile, the MIC value of fluconazole is decreased by 2-16 times, the sensitivity of fluconazole to cryptococcus is improved, so that the rattlerin not only is beneficial to reducing clinical dosage, but also is beneficial to slowing down the phenomenon of high drug resistance rate of cryptococcus, and conducts beneficialexploration for clinical anti-fungal infection.

The invention belongs to the technical field of medicaments, in particular relates to a benzocyclodirivative as shown in a general formula (I) as well as pharmaceutically acceptable salts, a hydras and an isomer thereof, wherein R1, R2, R3, R4, Q, X and Y are defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds in preparing medicaments for treating and / or preventing non-insulin-dependent diabetes mellitus.

The invention provides a drug composition for synergistically resisting a pancreatic cancer. The drug includes an active component and a pharmaceutically acceptable auxiliary material and is characterized in that the active component includes gemcitabine and a triterpenoid; and the triterpenoid is 3 alpha, 11 alpha-dihydroxy-lupin-20(29)-ene-28-acid or 3 alpha-hydroxy-lupin-20(29)-ene-23, 28-diacid. According to the drug composition, the synergistic effect of combined medication to pancreatic cancer cells is judged on various aspects of a pancreatic cancer cell growth state, a cell growth inhibition percentage, influences of cell cycle and apoptosis and the like; and due to the drug resistance of the gemcitabine, by adopting combined medication, more medication safety is provided, clinic use dosage of the gemcitabine is lowered, the toxic and side effects generated by using a large dosage of the gemcitabine are reduced, the clinic treatment safety index is improved, and more possibilities are provided for clinic application of the gemcitabine.

The invention belongs to the technical field of preparation of veterinary drugs and particularly relates to a veterinary enrofloxacin solid lipid nanosuspension and a preparation method thereof. The technological production of a preparation is implemented with a high-pressure homogenization technique. In terms of W / V, a suspension injection is prepared from 12%-35% of a solid lipid substrate, 2%-6% of crude enrofloxacin, 0.2%-4% of an active agent, 0.2%-1% of an antioxidant and the balance of sterile water. The solid lipid substrate is good in physiological compatibility and biodegradable, theencapsulation efficiency and drug loading capacity of nanoparticles are high, the preparation method is simple, the production cost is low, and large-scale industrial production is easy. The solid lipid nanosuspension has an obvious slow-release effect, in-vivo absorption and in-cell intake of active molecules can be increased, clinical administration times can be reduced, and the nanosuspensionis non-irritant to target animals and can be used for preventing and treating bacterial digestive tract and respiratory diseases of pigs and chicken.

The invention belongs to the technical field of medicaments, in particular relates to a benzocyclodirivative as shown in a general formula (I) as well as pharmaceutically acceptable salts, a hydras and an isomer thereof, wherein R1, R2, R3, R4, Q, X and Y are defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds in preparing medicaments for treating and / or preventing non-insulin-dependent diabetes mellitus.